Literature DB >> 15136557

MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4).

William Stohl1, Dong Xu, Kyoung Soo Kim, Chella S David, James P Allison.   

Abstract

One of the key downregulators of T cell activation is CD152 (CTLA-4). Mice genetically deficient in CD152 (cd152(-/-) mice) develop massive expansion of both CD4(+) and CD8(+) T cells as well as increased numbers of splenic Ig-secreting cells and serum Ig levels. To determine the dependence of the lymphoproliferation and B cell hyperactivity on MHC class II (MHCII), MHCII-deficient (mhcii(-/-)) cd152(-/-) mice were generated. Compared to that in their mhcii(+/+) counterparts, expansion of CD4(+) cells in mhcii(-/-)cd152(-/-) mice was markedly attenuated. Nonetheless, expansion of CD8(+) cells was identical in both sets of mice, demonstrating that the effects of CD152 deficiency on CD4(+) cells can quantitatively be dissociated from those on CD8(+) cells, and pointing to a critical downregulatory role for CD152 in MHCII-independent CD8(+) cell activation in vivo. B cell hyperactivity also developed in mhcii(-/-)cd152(-/-) mice, albeit in a manner less rapid and less intense than that in their mhcii(+/+) counterparts, demonstrating an underlying MHCII-independent diathesis to B cell dysregulation and pointing to a critical downregulatory role for CD152 in MHCII-independent B cell activation in vivo. When human DQ8 was introduced as a transgene into mhcii(-/-)cd152(-/-) mice, B cell hyperactivity was restored to levels observed in mhcii(+/+)cd152(-/-) mice, pointing to a critical downregulatory role for CD152 in MHCII-dependent B cell activation in vivo superimposed upon its downregulatory role on MHCII-independent B cell activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136557     DOI: 10.1093/intimm/dxh091

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  4 in total

1.  Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; Shunhua Guo; Laurence Morel
Journal:  Arthritis Rheum       Date:  2010-08

2.  Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF.

Authors:  Chaim O Jacob; Luminita Pricop; Chaim Putterman; Michael N Koss; Yi Liu; Maria Kollaros; Sarah A Bixler; Christine M Ambrose; Martin L Scott; William Stohl
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

3.  Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; William J Quinn; Michael P Cancro; Huaxin Gao; Chaim Putterman; Xiaoni Gao; Luminita Pricop; Michael N Koss
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

4.  Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice.

Authors:  William Stohl; Ning Yu; Samantha A Chalmers; Chaim Putterman; Chaim O Jacob
Journal:  Lupus Sci Med       Date:  2019-02-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.